by
Thomas Dworetzky, Contributing Reporter | June 30, 2017
Building a prototype “wasn't part of the original plan,” Katrina Pitas, SHINE Vice President, said at the time, adding that, “frankly, the reason we're breaking ground on that facility instead of the manufacturing facility is that we have raised money slower than we'd intended.”
And in March, the University of Missouri Research Reactor (MURR) along with its partners, Nordion, a business of Sterigenics International, and General Atomics (GA),
submitted a license amendment request (LAR) to the U.S. Nuclear Regulatory Commission (NRC) to begin making the isotope.
Ad Statistics
Times Displayed: 109903
Times Visited: 6641 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Calling the move a “critical step,” Nordion stated that the facility could provide “nearly half of U.S. demand for Mo-99, which currently must be imported from outside North America.”
"We will start receiving Mo-99 from MURR in mid-to late-2018," said Phil Larabie, vice president, Medical Isotopes for Nordion. "Filing this license amendment is a key step in our efforts to stabilize and support the nuclear medicine community in North America and beyond for decades to come."
In the June 2017 issue of DOTmed HealthCare Business News magazine Tiffany Olson, president, Nuclear Pharmacy Services, Cardinal Health
spoke about the Mo-99 challenge.
“When I started in the radiopharmaceutical industry in 2013, I was astonished at the complexity of the supply chain,” she recalled.
She went on to address the issue of shortages, stating that, “the Mo-99 supply shortage in 2009 created an impetus for the industry to focus on enhancing the reliability of supply. Over the last several years, the industry has increased outage reserve capacity and added extra targets at current reactors. Generator manufacturers, downstream to reactors, have diversified their supply chains and incorporated multi-source agreements for Mo-99. Industry groups such as the Organisation for Economic Co-operation and Development (OECD) are meeting with groups to ensure reactor maintenance schedules are coordinated. Mo-99 production has become more reliable with these additional reactors and processing capacity. We continue to monitor these conditions closely, and feel confident in the plans the industry has in place to minimize interruptions and ensure continuous supply for patients.”
Back to HCB News
